Metastatic Castration-resistant Prostate Cancer (mCRPC)
Conditions
Brief summary
rPFS (for radiographic progression-free survival) by BICR (Blinded Independent Central Review). The ability of BMS-986365 to work better than other treatments chosen by the doctors is tested by looking at the rPFS, which shows how long it takes for the disease to get worse by radiographic imaging techniques (like X-rays or scans)
Detailed description
OS (Overall Survival) This study will assess if people live longer when they take BMS-986365 compared to other treatments chosen by the doctors. This is what is called "Overall Survival".
Interventions
Sponsors
Celgene Corp.
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rPFS (for radiographic progression-free survival) by BICR (Blinded Independent Central Review). The ability of BMS-986365 to work better than other treatments chosen by the doctors is tested by looking at the rPFS, which shows how long it takes for the disease to get worse by radiographic imaging techniques (like X-rays or scans) | — |
Secondary
| Measure | Time frame |
|---|---|
| OS (Overall Survival) This study will assess if people live longer when they take BMS-986365 compared to other treatments chosen by the doctors. This is what is called "Overall Survival". | — |
Countries
Austria, Czechia, Denmark, France, Germany, Ireland, Italy, Poland, Romania, Slovakia, Spain, Sweden
Outcome results
None listed